The abstract is read at the publisher; the summary is JClub's.
CSF ctDNA tumor fraction detected by ultra-low-pass whole-genome sequencing in all baseline samples from seven breast cancer patients with leptomeningeal disease shows early reductions within 1–2 cycles on trastuzumab deruxtecan.
- Why it matters: Leptomeningeal disease from breast cancer has poor outcomes and lacks quantitative tools to assess treatment response, motivating a more sensitive biomarker for monitoring.
- What they did: In cohort 5 of the phase II DEBBRAH trial, serial CSF and plasma were analyzed using ulpWGS for ctDNA tumor fraction and targeted UMI-based sequencing for mutational profiling.
- The result: Early CSF ctDNA tumor fraction reductions within 1–2 cycles were associated with prolonged radiological control of LMD, while plasma ctDNA mainly tracked extracranial disease and showed compartmentalized genomic features.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.